[Skip to Content]
[Skip to Content Landing]
Views 140
Citations 0
Invited Commentary
July 23, 2020

Measuring Anatomical Outcomes of Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema With Artificial Intelligence—A Step Toward Individualized Medicine

Author Affiliations
  • 1Vision Research Center, Department of Ophthalmology, School of Medicine, University of Missouri–Kansas City, Kansas City, Missouri
  • 2Department of Biomedical Sciences, School of Medicine, University of Missouri–Kansas City, Kansas City, Missouri
JAMA Ophthalmol. Published online July 23, 2020. doi:10.1001/jamaophthalmol.2020.2464

Diabetic macular edema (DME) is the most common cause of visual dysfunction in patients with diabetes, with an estimated worldwide prevalence of 7.4%.1 In addition to its effects on individual quality of life, DME poses a significant economic burden on health care systems.2 As such, identifying the most efficient methods of treatment and factors associated with therapeutic success are prudent.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×